Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Lapatinib
Novartis Pharmaceuticals
Neoplasms, Breast
2 trials -
Ligelizumab
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
1 trial -
NIS793
Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma
1 trial -
Nilotinib
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
1 trial -
Nilotinib (AMN107)
Novartis Pharmaceuticals
Gastrointestinal Stromal Tumor (GIST)
1 trial -
OAV101
Novartis Pharmaceuticals
Spinal Muscular Atrophy
1 trial -
OFC Infusion
Novartis Pharmaceuticals
Leukaemia, Lymphocytic, Chronic
1 trial -
Ofatumumab
Novartis Pharmaceuticals
Leukaemia, Lymphocytic, Chronic
1 trial -
Panobinostat
Novartis Pharmaceuticals
Multiple Myeloma
1 trial -
Pelacarsen
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease (ASCVD)
1 trial -
Placebo
Novartis Pharmaceuticals
Ankylosing Spondylitis
1 trial -
Placebo
Novartis Pharmaceuticals
IC-MPGN
1 trial -
QAW039
Novartis Pharmaceuticals
Asthma
1 trial -
QAW039 150 mg
Novartis Pharmaceuticals
Asthma
1 trial -
QMF149
Novartis Pharmaceuticals
Asthma
1 trial -
QMF149 150/80 μg
Novartis Pharmaceuticals
Mild Asthma
1 trial -
QVA149
Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
QVM149 150/50/160
Novartis Pharmaceuticals
Asthma
1 trial -
RAD001
Novartis Pharmaceuticals
Tuberous Sclerosis Complex-associated Refractory Seizures
1 trial -
Ranibizumab
Novartis Pharmaceuticals
Retinopathy of Prematurity
1 trial -
Ranibizumab
Novartis Pharmaceuticals
Retinopathy of Prematurity (ROP)
1 trial -
Ranibizumab 0.5 mg
Novartis Pharmaceuticals
Central Retinal Vein Occlusion
1 trial -
Remibrutinib
Novartis Pharmaceuticals
Chronic Inducible Urticaria
1 trial -
Remibrutinib
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.